Supernus Pharmaceuticals (SUPN) Set to Announce Quarterly Earnings on Wednesday

Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.39 per share for the quarter. Supernus Pharmaceuticals has set its FY 2024 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.39). The firm had revenue of $164.30 million for the quarter, compared to analysts’ expectations of $155.03 million. Supernus Pharmaceuticals had a net margin of 0.22% and a return on equity of 0.14%. The business’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same period last year, the company posted $0.43 earnings per share. On average, analysts expect Supernus Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Supernus Pharmaceuticals Stock Up 1.9 %

Shares of NASDAQ SUPN opened at $30.83 on Monday. The firm’s 50-day moving average price is $31.72 and its 200-day moving average price is $28.80. Supernus Pharmaceuticals has a 52-week low of $21.99 and a 52-week high of $38.08.

Insider Activity

In related news, VP Padmanabh P. Bhatt sold 3,884 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $32.99, for a total value of $128,133.16. Following the transaction, the vice president now owns 8,570 shares of the company’s stock, valued at $282,724.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 12,364 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $35.31, for a total transaction of $436,572.84. Following the sale, the vice president now owns 8,570 shares in the company, valued at approximately $302,606.70. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 3,884 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total transaction of $128,133.16. Following the sale, the vice president now owns 8,570 shares in the company, valued at approximately $282,724.30. The disclosure for this sale can be found here. Insiders have sold a total of 35,739 shares of company stock valued at $1,227,433 in the last 90 days. 8.76% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Separately, Piper Sandler dropped their price target on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a report on Wednesday, February 28th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.